DE3643001C2 - - Google Patents
Info
- Publication number
- DE3643001C2 DE3643001C2 DE3643001A DE3643001A DE3643001C2 DE 3643001 C2 DE3643001 C2 DE 3643001C2 DE 3643001 A DE3643001 A DE 3643001A DE 3643001 A DE3643001 A DE 3643001A DE 3643001 C2 DE3643001 C2 DE 3643001C2
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical compositions
- leukemia
- treatment
- radiation
- niobium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 208000032839 leukemia Diseases 0.000 claims description 15
- 208000030507 AIDS Diseases 0.000 claims description 9
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000002604 lanthanum compounds Chemical class 0.000 claims description 4
- YHBDIEWMOMLKOO-UHFFFAOYSA-I pentachloroniobium Chemical compound Cl[Nb](Cl)(Cl)(Cl)Cl YHBDIEWMOMLKOO-UHFFFAOYSA-I 0.000 claims description 4
- 229910052845 zircon Inorganic materials 0.000 claims description 3
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 claims description 3
- 229910002422 La(NO3)3·6H2O Inorganic materials 0.000 claims description 2
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 claims description 2
- FWIYBTVHGYLSAZ-UHFFFAOYSA-I pentaiodoniobium Chemical compound I[Nb](I)(I)(I)I FWIYBTVHGYLSAZ-UHFFFAOYSA-I 0.000 claims description 2
- DANYXEHCMQHDNX-UHFFFAOYSA-K trichloroiridium Chemical compound Cl[Ir](Cl)Cl DANYXEHCMQHDNX-UHFFFAOYSA-K 0.000 claims description 2
- KOECRLKKXSXCPB-UHFFFAOYSA-K triiodobismuthane Chemical compound I[Bi](I)I KOECRLKKXSXCPB-UHFFFAOYSA-K 0.000 claims description 2
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 2
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 11
- 230000005855 radiation Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 230000005865 ionizing radiation Effects 0.000 description 5
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 235000011569 Armillaria mellea Nutrition 0.000 description 2
- 244000221226 Armillaria mellea Species 0.000 description 2
- 241000191897 Microglossum viride Species 0.000 description 2
- 241000123672 Strophariaceae Species 0.000 description 2
- 241000222433 Tricholomataceae Species 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052758 niobium Inorganic materials 0.000 description 2
- 239000010955 niobium Substances 0.000 description 2
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000121326 Clavariaceae Species 0.000 description 1
- 241000026124 Clavariadelphus ligula Species 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241001465240 Helvellaceae Species 0.000 description 1
- 241001561504 Hemipholiota populnea Species 0.000 description 1
- 241000123392 Hymenochaetaceae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001237938 Kuehneromyces Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001534110 Lactarius <percoid fish> Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221701 Pezizaceae Species 0.000 description 1
- 241000123129 Phaeolus schweinitzii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 208000005818 Radiation-Induced Leukemia Diseases 0.000 description 1
- 241000221986 Russulaceae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000246420 Sarcosphaera Species 0.000 description 1
- 241000959596 Scleroderma citrinum Species 0.000 description 1
- 241001503959 Sclerodermataceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010889 donnan-equilibrium Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000035851 morphological anomaly Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863643001 DE3643001A1 (de) | 1986-12-17 | 1986-12-17 | Pharmazeutische zusammensetzung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863643001 DE3643001A1 (de) | 1986-12-17 | 1986-12-17 | Pharmazeutische zusammensetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3643001A1 DE3643001A1 (de) | 1988-06-23 |
| DE3643001C2 true DE3643001C2 (enrdf_load_stackoverflow) | 1988-09-22 |
Family
ID=6316338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863643001 Granted DE3643001A1 (de) | 1986-12-17 | 1986-12-17 | Pharmazeutische zusammensetzung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3643001A1 (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE911559A1 (en) * | 1990-05-08 | 1991-11-20 | Johnson Matthey Plc | Improvements in chemical compounds |
| EP0624092A1 (fr) * | 1992-01-28 | 1994-11-17 | I.R.2.M. | Utilisation des derives du niobium comme principe actif de medicaments utiles dans le traitement et/ou la prevention des desordres du metabolisme des glucides et/ou des lipides |
| FR2686515B1 (fr) * | 1992-01-28 | 1994-04-29 | Ir2M | Utilisation des derives du niobium comme principe actif de medicaments utiles dans le traitement et/ou la prevention des desordres du metabolisme des glucides et/ou des lipides. |
| GB0022922D0 (en) * | 2000-09-19 | 2000-11-01 | Chapman Robert E | Compounds for use in medicine |
-
1986
- 1986-12-17 DE DE19863643001 patent/DE3643001A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3643001A1 (de) | 1988-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60223670T2 (de) | Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. | |
| DE69034206T2 (de) | Argininantagonisten zur Hemmung des systemischen Blutdruckes in Zusammenhang mitStickoxidbildung oder Endothelial Derived Relaxing Factor | |
| EP0359981B1 (de) | Pharmazeutische Kombinationspräparate und deren Verwendung als antineoplastische Arzneimittel | |
| DE60202278T2 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
| DE1792295B1 (de) | Pharmazeutisches Praeparat enthaltend 1-Aminomethyladamantan | |
| DE68902581T2 (de) | Pharmazeutische zusammensetzungen mit krebshemmender wirkung. | |
| DE69215999T2 (de) | Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs | |
| DE69812100T2 (de) | Adenosin enthaltendes arzneimittel | |
| CH654212A5 (de) | Zubereitung zur steigerung der therapeutischen wirkung eines antitumormittels und diese zubereitung enthaltende antitumor-zubereitung. | |
| CH665355A5 (de) | Pharmazeutische zusammensetzung. | |
| DE3643001C2 (enrdf_load_stackoverflow) | ||
| DE3638124C2 (de) | Neue pharmazeutische Verwendung von Ebselen | |
| DE2709506C2 (de) | Verwendung von 10-Deazaminopterin zur Behandlung von Leukämie und ascitischen Tumoren | |
| EP2047855B1 (de) | Antitumorale, antibakterielle und antivirale pharmazeutische zusammensetzung (varianten) | |
| EP0007597B1 (de) | N-Niedrigalkylglycinamide und Sarkosinanhydrid sowie in Kombination mit bekannten tumorhemmenden Verbindungen vorliegendes Sarkosin zur Anwendung bei der Heilung von Tumoren sowie dieselben enthaltendes Mittel und Verfahren zu dessen Herstellung | |
| DE3875859T2 (de) | Zubereitungen zur verbesserung der adcc-therapien. | |
| EP0398165A1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| DE69408394T2 (de) | 4-Piperidino-piperidin zur Behandlung von Tumoren | |
| DE19530708C2 (de) | Pharmazeutisches Präparat mit trypanoziden Eigenschaften | |
| EP0223850B1 (de) | Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten | |
| DE4127469A1 (de) | Arzneimittel und ihre verwendung | |
| DE68905082T2 (de) | Virushemmende pharmazeutische zusammensetzung. | |
| DE1767540C2 (de) | Mittel zur Behandlung von Histomoniasis bei der Geflügelzucht | |
| DE3782661T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs. | |
| EP0285906A2 (de) | Wirkstoff zur Tumorbekämpfung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |